Table 5 Adverse events in the study
| Â | No. of patients with CTCAE grade (%) | |||
|---|---|---|---|---|
Adverse event | 1 (%) | 2 (%) | 3 (%) | 4 (%) |
AST/ALT | 21 (55.3) | 6 (15.8) | 4 (10.5) | 1 (2.6) |
Alkaline-phosphatase | 3 (7.9) | – | – | – |
Bilirubin | 12 (31.6) | 2 (5.3) | 3 (7.9) | 2 (5.3) |
Gastroduodenitis | 2 (5.3) | 1 (2.6) | – | – |
Gastric ulcer | 2 (5.3) | – | 1 (2.6) | – |
Duodenal ulcer | 1 (2.6) | 1 (2.6) | – | – |